All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to select the best regimen at first relapse. The recorded discussion was chaired by Professor María-Victoria Mateos and featured Sagar Lonial, Morie Gertz, Paul Richardson, Heinz Ludwig, Hermann Einsele, Sonja Zweegman, and Mohamad Mohty.
Selecting the best regimen at first relapse
The panel discussed treatment options and challenges for different patient populations at first relapse, and the factors that can affect treatment options. Some of these factors are demographic (e.g., age), clinical (e.g., frailty), and treatment-related (e.g., first-line treatment).
This discussion focusses on two patient scenarios, one being a lenalidomide-sensitive patient and the other being a lenalidomide-resistant patient. The conversation opens with discussion on the rarity of the lenalidomide-sensitive scenario and the recommended treatment following the results of the POLLUX trial. The discussion then continues with the lenalidomide-resistant scenario, where the experts evaluated studies such as APOLLO, i.e., daratumumab plus pomalidomide and dexamethasone (DaraPomDex), and carfilzomib in combination with daratumumab and dexamethasone (Dara-Kd), considering progression-free survival and potential further lines of treatment. The experts also considered the impact that COVID-19 has had on the way treatment is administered and concluded with a discussion on frailty as a factor determining treatment options.
Additional questions raised and discussed included:
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox